Join to View Full Profile
300 Pasteur DrStanford, CA 94305
Phone+1 650-723-4000
Are you Dr. Miller?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Richard Miller, MD is an oncologist in Stanford, California. He is currently licensed to practice medicine in California.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1977 - 1980- Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1975 - 1977
State University of New York Downstate Medical Center College of MedicineClass of 1975
Certifications & Licensure
CA State Medical License 1976 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 13 citationsAnti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer.Richard A Miller, Jason John Luke, Shenshen Hu, Suresh Mahabhashyam, William B Jones
Journal for Immunotherapy of Cancer. 2022-12-01 - 144 citationsAdenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell CancerLawrence Fong, Andrew Hotson, John D. Powderly, Mario Sznol, Rebecca S. Heist
Cancer Discovery. 2020-01-01 - 133 citationsA2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical ModelsStephen Willingham, Po Y. Ho, Andrew Hotson, Craig M. Hill, Emily Piccione
Cancer Immunology Research. 2018-01-01
Press Mentions
Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual MeetingMarch 15th, 2023
The Expanding Circle of ImmunotherapySeptember 20th, 2019
Corvus Pharmaceuticals Presents Initial CPI-006 Phase 1/1b Clinical Data at 2019 ASCO Annual MeetingJune 2nd, 2019- Join now to see all
